Zacks Investment Research upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a hold rating to a buy rating in a research note published on Wednesday morning. The firm currently has $40.00 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Several other research firms have also issued reports on ADMS. Cowen set a $55.00 target price on shares of Adamas Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, December 13th. Northland Securities assumed coverage on shares of Adamas Pharmaceuticals in a report on Wednesday, November 29th. They issued an outperform rating for the company. BidaskClub lowered shares of Adamas Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, December 14th. Piper Jaffray Companies set a $52.00 target price on shares of Adamas Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, December 19th. Finally, Noble Financial increased their target price on shares of Adamas Pharmaceuticals from $33.00 to $48.00 and gave the stock a buy rating in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $44.86.

Adamas Pharmaceuticals (NASDAQ ADMS) opened at $34.03 on Wednesday. Adamas Pharmaceuticals has a one year low of $13.50 and a one year high of $38.22. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). During the same period in the previous year, the company posted ($0.66) EPS. The company’s revenue for the quarter was down 99.3% compared to the same quarter last year. equities analysts forecast that Adamas Pharmaceuticals will post -3.84 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $606,000. Granite Point Capital Management L.P. grew its holdings in Adamas Pharmaceuticals by 11.9% during the 2nd quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock valued at $4,609,000 after buying an additional 28,000 shares in the last quarter. Hikari Power Ltd purchased a new stake in Adamas Pharmaceuticals during the 3rd quarter valued at approximately $635,000. EAM Investors LLC purchased a new stake in Adamas Pharmaceuticals during the 3rd quarter valued at approximately $1,795,000. Finally, Vanguard Group Inc. grew its holdings in Adamas Pharmaceuticals by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock valued at $13,034,000 after buying an additional 28,818 shares in the last quarter. 79.40% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.mareainformativa.com/adamas-pharmaceuticals-adms-lifted-to-buy-at-zacks-investment-research/123575/.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.